Loading
Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease.
Georgina Long (Melanoma Institute Australia) led COMBI-d and COMBI-AD, the trials establishing dabrafenib plus trametinib in metastatic and adjuvant BRAF-mutant melanoma, and co-led NADINA, which showed neoadjuvant nivolumab plus ipilimumab beats adjuvant nivolumab in stage III melanoma and is changing the sequence of surgery and immunotherapy. She also led the ABC trial of immunotherapy for melanoma brain metastases and was 2024 Australian of the Year with Richard Scolyer.
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors and the tags melanoma, neoadjuvant.
Shares Stage III melanoma (after surgery), PD-1, Melanoma, Immune checkpoint inhibitors and the tags melanoma, neoadjuvant.
Shares BRAF V600-mutant melanoma, BRAF, Ipilimumab, Nivolumab and the tag melanoma.
Shares BRAF, Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
Shares NADINA, NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma, Stage III melanoma (after surgery), Ipilimumab.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
Shares Stage III melanoma (after surgery), Ipilimumab, Nivolumab, PD-1 and the tag melanoma.